Probiotics for the Primary and Secondary Prevention of C. difficile Infections: A Meta-analysis and Systematic Review
Open accessThe DOI matches its Crossref record; 59 of the 60 references it cites were found in a registry or an index.
Abstract
Clostridium difficile infections are a global clinical concern and are one of the leading causes of nosocomial outbreaks. Preventing these infections has benefited from multidisciplinary infection control strategies and new antibiotics, but the problem persists. Probiotics are effective in preventing antibiotic-associated diarrhea and may also be a beneficial strategy for C. difficile infections, but randomized controlled trials are scarce. This meta-analysis pools 21 randomized, controlled trials for primary prevention of C. difficile infections (CDI) and four trials for secondary prevention of C. difficile recurrences and assesses the efficacy of specific probiotic strains. Four probiotics significantly improved primary CDI prevention: (Saccharomyces boulardii, Lactobacillus casei DN114001, a mixture of L. acidophilus and Bifidobacterium bifidum, and a mixture of L. acidophilus, L. casei and L. rhamnosus). None of the tested probiotics significantly improved secondary prevention of CDI. More confirmatory randomized trials are needed to establish if probiotics are useful for preventing C. difficile infections. v
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139 · cited 1×
“Heterogeneity across trials was evaluated using Cochran Q test based on pooled relative risks by the Mantel-Haenazel method [54].”
MethodBias in meta-analysis detected by a simple, graphical test
Egger, M., Smith, G. D., Schneider, M., & Minder, C. (1997) · BMJ · doi:10.1136/bmj.315.7109.629 · Cited by 56,722 · cited 2×
“This meta-analysis followed PRISMA (Preferred Reporting Items for Systematic reviews and Meta-Analysis) statement guidelines [51] and guidelines using clearly delineated parameters, a priori inclusion and exclusion criteria and standardized data extraction tools [52,53] Systematic searches of PubMed (1960–2015), EMBAS…”
MethodLiberati, A., Altman, D. G., Tetzlaff, J., Mulrow, C., Gøtzsche, P. C., Ioannidis, J. P. A., Clarke, M., Devereaux, P. J., Kleijnen, J., & Moher, D. (2009) · PLoS Medicine · doi:10.1371/journal.pmed.1000100 · Cited by 28,164
Liberati, A., Altman, D. G., Tetzlaff, J., Mulrow, C., Gotzsche, P. C., Ioannidis, J. P. A., Clarke, M., Devereaux, P. J., Kleijnen, J., & Moher, D. (2009) · BMJ · doi:10.1136/bmj.b2700 · Cited by 17,648
Operating characteristics of a rank correlation test for publication bias
Begg, C. B., & Mazumdar, M. (1994) · Biometrics · doi:10.2307/2533446 · Cited by 16,955 · cited 1×
“To assess for publication bias, a funnel plot, as well as a weighted regression (Egger’s test) and a rank correlation test (Begg’s test for small study effects) were conducted [52,55].”
MethodMoher, D., Hopewell, S., Schulz, K. F., Montori, V., Gotzsche, P. C., Devereaux, P. J., Elbourne, D., Egger, M., & Altman, D. G. (2010) · BMJ · doi:10.1136/bmj.c869 · Cited by 8,883
Burden of Clostridium difficile Infection in the United States
Lessa, F. C., Mu, Y., Bamberg, W. M., Beldavs, Z. G., Dumyati, G. K., Dunn, J. R., Farley, M. M., Holzbauer, S. M., Meek, J. I., Phipps, E. C., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1408913 · Cited by 2,641 · cited 1×
“[1].”
Comparison of two methods to detect publication bias in meta-analysis.
Peters, J. L. (2006) · JAMA · doi:10.1001/jama.295.6.676 · Cited by 2,278 · cited 1×
“Reporting bias (smaller studies showing no protective effect) often are not published, and are indicated by an asymmetrical appearance with a gap in the bottom left of a funnel plot [56].”
BackgroundMoher, D., Hopewell, S., Schulz, K. F., Montori, V., Gøtzsche, P. C., Devereaux, P. J., Elbourne, D., Egger, M., & Altman, D. G. (2010) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2010.03.004 · Cited by 1,858
Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections
Surawicz, C. M., Brandt, L. J., Binion, D. G., Ananthakrishnan, A. N., Curry, S. R., Gilligan, P. H., McFarland, L. V., Mellow, M., & Zuckerbraun, B. S. (2013) · American Journal of Gastroenterology · doi:10.1038/ajg.2013.4 · Cited by 1,645
Self-citationProbiotic Mechanisms of Action
Bermudez-Brito, M., Plaza-Díaz, J., Muñoz-Quezada, S., Gómez-Llorente, C., & Gil, A. (2012) · Annals of Nutrition and Metabolism · doi:10.1159/000342079 · Cited by 1,234 · cited 1×
“I would disagree with this hypothesis, as different probiotic strains can have different mechanisms-of-action and resulting degrees of efficacies [47].”
BackgroundMcFarland, L. V. (2006) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2006.00465.x · Cited by 872 · cited 2×
“Some probiotic strains have been found to be effective for prevention of antibiotic-associated diarrhea (AAD) and for the treatment of CDI [5].”
BackgroundMethodSelf-citationMcFarland, L. V. (1994) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1994.03510480037031 · Cited by 857 · cited 6×
“Of the four trials, three reported attrition rates from no attrition [39,41], to 16% attrition [38], but attrition was not reported in one trial [40].”
BackgroundInfluentialSelf-citationProbiotics for the prevention of Clostridium difficile-associated diarrhea in adults and children
Goldenberg, J. Z., Ma, S. S., Saxton, J. D., Martzen, M. R., Vandvik, P. O., Thorlund, K., Guyatt, G. H., & Johnston, B. C. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006095.pub3 · Cited by 741
Breaking The Cycle: Treatment Strategies for 163 Cases of Recurrent Clostridium Difficile Disease
McFarland, L. V., Elmer, G. W., & Surawicz, C. M. (2002) · American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2002.05839.x · Cited by 724 · cited 1×
“difficile antibiotics can be determined [57,58].”
Self-citationHickson, M., D'Souza, A. L., Muthu, N., Rogers, T. R., Want, S., Rajkumar, C., & Bulpitt, C. J. (2007) · BMJ · doi:10.1136/bmj.39231.599815.55 · Cited by 599 · cited 3×
“5 only 34% with VAP on abx nr pneumonia Morrow 2010 [29] adults, I 19 61% single 66% amox or cepha 49% resp Hickson 2007 [30] adults, I 0 nr 60% amp or cepha 80% resp or GU Dietrich 2014 [31] elderly, I 8 nr nr nr Plummer 2004 [32] adults, I 0 nr mixed nr Rafiq 2007 [33] adults, I 0 nr 48% ceph nr Stein 2007 [34] adul…”
BackgroundSystematic review and meta-analysis of Saccharomyces boulardii in adult patients
McFarland, L. V. (2010) · World Journal of Gastroenterology · doi:10.3748/wjg.v16.i18.2202 · Cited by 545 · cited 1×
“difficile antibiotics can be determined [57,58].”
Self-citationSurawicz, C. M., McFarland, L. V., Greenberg, R. N., Rubin, M., Fekety, R., Mulligan, M. E., Garcia, R. J., Brandmarker, S., Bowen, K., Borjal, D., et al. (2000) · Clinical Infectious Diseases · doi:10.1086/318130 · Cited by 529 · cited 7×
“Of the four trials, three reported attrition rates from no attrition [39,41], to 16% attrition [38], but attrition was not reported in one trial [40].”
BackgroundInfluentialSelf-citationArvola, T., Laiho, K., Torkkeli, S., Mykkänen, H., Salminen, S., Maunula, L., & Isolauri, E. (1999) · Pediatrics · doi:10.1542/peds.104.5.e64 · Cited by 427 · cited 5×
“For primary CDI prevention, 21 trials (23 treatment arms) were included [17–37] and for secondary CDI prevention, four trials (six treatment arms) were included [38–41].”
BackgroundInfluentialWorld Gastroenterology Organisation Global Guidelines: Probiotics and Prebiotics October 2011
Guarner, F., Khan, A. G., Garisch, J., Eliakim, R., Gangl, A., Thomson, A., Krabshuis, J., Lemair, T., Kaufmann, P., de Paula, J. A., et al. (2012) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0b013e3182549092 · Cited by 418 · cited 1×
“As research on probiotics has evolved, the efficacy and mechanisms-of-action has been found to be highly strain-specific, requiring that dissimilar types of probiotics to be analyzed as separate subgroups [44].”
BackgroundPrevention of beta-lactam-associated diarrhea by Saccharomyces boulardii compared with placebo.
McFarland, L. V., Surawicz, C. M., Greenberg, R. N., Elmer, G. W., Moyer, K. A., Melcher, S. A., Bowen, K., & Cox, J. L. (1995) · PubMed · Cited by 383
Self-citationJohnston, B. C., Ma, S. S. Y., Goldenberg, J. Z., Thorlund, K., Vandvik, P. O., Loeb, M., & Guyatt, G. H. (2012) · Annals of Internal Medicine · doi:10.7326/0003-4819-157-12-201212180-00563 · Cited by 367
Probiotic Prophylaxis of Ventilator-associated Pneumonia: A Blinded, Randomized, Controlled Trial
Morrow, L. E., Kollef, M. H., & Casale, T. B. (2010) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200912-1853oc · Cited by 346 · cited 3×
“5 only 34% with VAP on abx nr pneumonia Morrow 2010 [29] adults, I 19 61% single 66% amox or cepha 49% resp Hickson 2007 [30] adults, I 0 nr 60% amp or cepha 80% resp or GU Dietrich 2014 [31] elderly, I 8 nr nr nr Plummer 2004 [32] adults, I 0 nr mixed nr Rafiq 2007 [33] adults, I 0 nr 48% ceph nr Stein 2007 [34] adul…”
BackgroundGao, X. W., Mubasher, M., Fang, C. Y., Reifer, C., & Miller, L. E. (2010) · American Journal of Gastroenterology · doi:10.1038/ajg.2010.11 · Cited by 318 · cited 2×
“Of the 25 randomized controlled trials included, three had multiple treatment arms, [28,37,39] resulting in a total of 29 treatment arms, totaling 4476 participants.”
BackgroundKotowska, M., Albrecht, P., & Szajewska, H. (2005) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2005.02356.x · Cited by 286 · cited 3×
“As shown in Table 2, most of the 21 trials enrolled adult participants (n=18, 86%) and three (14%) enrolled children [21,25,26], and all trials included both genders.”
BackgroundMiller, M., Gravel, D., Mulvey, M., Taylor, G., Boyd, D., Simor, A., Gardam, M., McGeer, A., Hutchinson, J., Moore, D., et al. (2010) · Clinical Infectious Diseases · doi:10.1086/649213 · Cited by 278 · cited 4×
“Of the 25 randomized controlled trials included, three had multiple treatment arms, [28,37,39] resulting in a total of 29 treatment arms, totaling 4476 participants.”
BackgroundInfluentialPrevention of antibiotic‐associated diarrhea in children by Clostridium butyricum MIYAIRI
SEKI, H., SHIOHARA, M., MATSUMURA, T., MIYAGAWA, N., TANAKA, M., KOMIYAMA, A., & KURATA, S. (2003) · Pediatrics International · doi:10.1046/j.1442-200x.2003.01671.x · Cited by 253 · cited 1×
“butyricum 588 mixed, 87% beta-lactams 1–4 × 10(7) 6 days 0 0/83 (0%) ns 0/27 (0%) Seki 2003 [11] L rhamnosus (strains E/N, Oxy, Pen) mixed, mostly pen and ceph 4 × 10(10) duration (x = 8 day) 2 weeks 3/120 (2.”
Plummer, S. F., Weaver, M. A., Harris, J. C., Dee, P., & Hunter, J. O. (2004) · PubMed · Cited by 251
The effect of probiotics on clostridium difficile diarrhea
POCHAPIN, M. (2000) · The American Journal of Gastroenterology · doi:10.1016/s0002-9270(99)00809-6 · Cited by 227 · cited 6×
“Of the four trials, three reported attrition rates from no attrition [39,41], to 16% attrition [38], but attrition was not reported in one trial [40].”
BackgroundInfluentialWullt, M., Hagslätt, M.-L. J., & Odenholt, I. (2003) · Scandinavian Journal of Infectious Diseases · doi:10.1080/00365540310010985 · Cited by 221 · cited 1×
“5 weeks 4/11 (36%) recurred 6/9 (67%) Wullt 2003 [16]”
THOMAS, M. R., LITIN, S. C., OSMON, D. R., CORR, A. P., WEAVER, A. L., & LOHSE, C. M. (2001) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(11)62106-x · Cited by 185 · cited 2×
“Four treatment arms gave the probiotic for a prescribed period (ranging from 14–21 days), regardless of the duration of antibiotics [23,27,32,34].”
BackgroundTreatment of recurrent Clostridium difficile colitis with vancomycin and Saccharomyces boulardii.
Surawicz, C. M., McFarland, L. V., Elmer, G., & Chinn, J. (1989) · PubMed · Cited by 179
Self-citationLewis, S. J., Potts, L. F., & Barry, R. E. (1998) · Journal of Infection · doi:10.1016/s0163-4453(98)80008-x · Cited by 171
Beausoleil, M., Fortier, N., Guénette, S., L’Ecuyer, A., Savoie, M., Franco, M., Lachaîne, J., & Weiss, K. (2007) · Canadian Journal of Gastroenterology · doi:10.1155/2007/720205 · Cited by 162 · cited 1×
“5 only 34% with VAP on abx nr pneumonia Morrow 2010 [29] adults, I 19 61% single 66% amox or cepha 49% resp Hickson 2007 [30] adults, I 0 nr 60% amp or cepha 80% resp or GU Dietrich 2014 [31] elderly, I 8 nr nr nr Plummer 2004 [32] adults, I 0 nr mixed nr Rafiq 2007 [33] adults, I 0 nr 48% ceph nr Stein 2007 [34] adul…”
BackgroundRUSZCZYŃSKI, M., RADZIKOWSKI, A., & SZAJEWSKA, H. (2008) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2008.03714.x · Cited by 130 · cited 2×
“8%) Ruszczynski 2008 [12] L.”
BackgroundPattani, R., Palda, V. A., Hwang, S. W., & Shah, P. S. (2013) · PubMed Central · Cited by 123
Prevention of antibiotic-associated diarrhoea by a fermented probiotic milk drink
Wenus, C., Goll, R., Loken, E. B., Biong, A. S., Halvorsen, D. S., & Florholmen, J. R. (2007) · European Journal of Clinical Nutrition · doi:10.1038/sj.ejcn.1602718 · Cited by 121 · cited 2×
“4%) Wenus 2008 [13] L.”
BackgroundIs primary prevention of Clostridium difficile infection possible with specific probiotics?
Johnson, S., Maziade, P.-J., McFarland, L. V., Trick, W., Donskey, C., Currie, B., Low, D. E., & Goldstein, E. J. C. (2012) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2012.06.005 · Cited by 117 · cited 3×
“However, studies of CDI prevention and probiotics have been largely limited to CDI being evaluated as a secondary outcome of AAD studies, leading to underpowerment for CDI outcomes [6].”
BackgroundMethodSelf-citationLönnermark, E., Friman, V., Lappas, G., Sandberg, T., Berggren, A., & Adlerberth, I. (2010) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0b013e3181b2683f · Cited by 110
Pozzoni, P., Riva, A., Bellatorre, A. G., Amigoni, M., Redaelli, E., Ronchetti, A., Stefani, M., Tironi, R., Molteni, E. E., Conte, D., et al. (2012) · American Journal of Gastroenterology · doi:10.1038/ajg.2012.56 · Cited by 106 · cited 2×
“6 100% single 100% amox 88% resp Bravo 2008 [23] adults, I 26 69% single mixed, nr nr Pozzoni 2012 [24] pediatric, I 15 nr 52% cepha resp Shan 2014 [25] pediatric, O 28.”
BackgroundDuman, D. G., Bor, S., ??z??temiz, ?., ??ahin, T., O??uz, D., I??tan, F., Vural, T., Sandkci, M., I??ksal, F., ??im??ek, ?., et al. (2005) · European Journal of Gastroenterology & Hepatology · doi:10.1097/00042737-200512000-00015 · Cited by 104 · cited 6×
“pylori infections Duman 2005 [20] pediatric, I&O 8.”
BackgroundMethodInfluentialCan, M., Beşirbellioglu, B. A., Avcı, İ. Y., Beker, C. M., & Pahsa, A. (2006) · PubMed · Cited by 101
Probiotics for recurrent Clostridium difficile disease
Lawrence, S. J., Korzenik, J. R., & Mundy, L. M. (2005) · Journal of Medical Microbiology · doi:10.1099/jmm.0.46096-0 · Cited by 101 · cited 6×
“Of the four trials, three reported attrition rates from no attrition [39,41], to 16% attrition [38], but attrition was not reported in one trial [40].”
BackgroundInfluentialSelinger, C. P., Bell, A., Cairns, A., Lockett, M., Sebastian, S., & Haslam, N. (2013) · Journal of Hospital Infection · doi:10.1016/j.jhin.2013.02.019 · Cited by 93 · cited 1×
“VSL#3 mixed, 75% pen 9 × 10(11) duration + 1 week 3 weeks 0/117 (0%) ns 0/112 (0%) Selinger 2013 [15]”
Dietrich, C. G. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i42.15837 · Cited by 90 · cited 3×
“5 only 34% with VAP on abx nr pneumonia Morrow 2010 [29] adults, I 19 61% single 66% amox or cepha 49% resp Hickson 2007 [30] adults, I 0 nr 60% amp or cepha 80% resp or GU Dietrich 2014 [31] elderly, I 8 nr nr nr Plummer 2004 [32] adults, I 0 nr mixed nr Rafiq 2007 [33] adults, I 0 nr 48% ceph nr Stein 2007 [34] adul…”
BackgroundWong, S., Jamous, A., O'Driscoll, J., Sekhar, R., Weldon, M., Yau, C. Y., Hirani, S. P., Grimble, G., & Forbes, A. (2014) · British Journal of Nutrition · doi:10.1017/s0007114513002973 · Cited by 79 · cited 2×
“2%) Wong 2014 [7] L.”
BackgroundShan, L.-S., Hou, P., Wang, Z.-J., Liu, F.-R., Chen, N., Shu, L.-H., Zhang, H., Han, X.-H., Han, X.-X., Cai, X.-X., et al. (2013) · Beneficial Microbes · doi:10.3920/bm2013.0008 · Cited by 73
Dylewski, J., Psaradellis, E., & Sampalis, J. (2010) · Archives of Medical Science · doi:10.5114/aoms.2010.13508 · Cited by 72
Auclair, J., Frappier, M., & Millette, M. (2015) · Clinical Infectious Diseases · doi:10.1093/cid/civ179 · Cited by 67
Allen, S., Wareham, K., Wang, D., Bradley, C., Sewell, B., Hutchings, H., Harris, W., Dhar, A., Brown, H., Foden, A., et al. (2013) · Health Technology Assessment · doi:10.3310/hta17570 · Cited by 56 · cited 2×
“2%) Allen 2013 [14]”
BackgroundSafdar, N., Barigala, R., Said, A., & McKinley, L. (2008) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/j.1365-2710.2008.00980.x · Cited by 50
Saccharomyces boulardii CNCM I-745 in different clinical conditions
Dinleyici, E. C., Kara, A., Ozen, M., & Vandenplas, Y. (2014) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2014.937419 · Cited by 49 · cited 2×
“The most current strain designation for S. boulardii is CNCM I-745, the registration number at the Pasteur Institute [42], but older studies also refer to this strain as S. boulardii lyo, or S. boulardii, with no strain designation or by the brand name “Florastor”.”
BackgroundAvadhani, A., & Miley, H. (2011) · Journal of the American Academy of Nurse Practitioners · doi:10.1111/j.1745-7599.2011.00617.x · Cited by 47 · cited 1×
“Previous meta-analyses on probiotics for the prevention of CDI done before these guidelines were established pooled dissimilar types of probiotic species in their analysis [5,45].”
Bravo, M. V., Bunout, D. C., Leiva, L., de la Maza, M. P., Barrera, G., de la Maza, J., & Hirsch, S. (2008) · Revista médica de Chile · Cited by 44
Maziade, P.-J., Andriessen, J. A., Pereira, P., Currie, B., & Goldstein, E. J. C. (2013) · Current Medical Research and Opinion · doi:10.1185/03007995.2013.833501 · Cited by 40 · cited 1×
“rhamnosus (BioK+) to all patients receiving antibiotics at two hospitals over time and found a significant reduction in the incidence of CDI cases and recurrences at these facilities [4].”
BackgroundMcFarland, L. V. (2013) · World Journal of Meta-Analysis · doi:10.13105/wjma.v1.i3.102 · Cited by 33 · cited 1×
“More recent meta-analyses have presented their results by probiotic sub-groups, but were not as comprehensive as this meta-analysis: One meta-analysis included 11 trials [6] and another was only done in five pediatric trials [49].”
Self-citationMartin, M., Zingg, W., Knoll, E., Wilson, C., & Dettenkofer, M. (2014) · Journal of Hospital Infection · doi:10.1016/j.jhin.2014.05.002 · Cited by 28 · cited 1×
“Prevention of CDI has relied on multidisciplinary infection control practices, but guidelines have been found to be difficult to implement globally [2,3].”
Background[Probiotics as prophylactic agents against antibiotic-associated diarrhea in hospitalized patients].
Stein, G. Y., Nanim, R., Karniel, E., Moskowitz, I., & Zeidman, A. (2007) · PubMed · Cited by 20
Moher, D. (2010) · Journal of Clinical Epidemiology · Cited by 7
Research works printed but not linked: 1
- Rafiq, 2007, Prevention of Clostridium difficile (C. difficile) diarrhea with probiotic in hospitalized patients treated with antibiotics, Gastroenterology, 132, A187
Cited by
A review of dose-responses of probiotics in human studies
Ouwehand, A. C. (2017) · Beneficial Microbes · doi:10.3920/bm2016.0140 · Cited by 233
“McFarland, in a later meta-analysis of 21 primary CDAD studies with 14 probiotic formulations, noted that a similar moderate efficacy for studies with doses less than 10 10 cfu and those with larger doses (McFarland, 2015).”
Den, H., Dong, X., Chen, M., & Zou, Z. (2020) · Aging · doi:10.18632/aging.102810 · Cited by 230
Antimicrobial Activity of Lactobacillus Species Against Carbapenem-Resistant Enterobacteriaceae
Chen, C.-C., Lai, C.-C., Huang, H.-L., Huang, W.-Y., Toh, H.-S., Weng, T.-C., Chuang, Y.-C., Lu, Y.-C., & Tang, H.-J. (2019) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.00789 · Cited by 200
Cross-Domain and Viral Interactions in the Microbiome
Rowan-Nash, A. D., Korry, B. J., Mylonakis, E., & Belenky, P. (2019) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.00044-18 · Cited by 163
McFarland, L. V., Ozen, M., Dinleyici, E. C., & Goh, S. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i11.3078 · Cited by 153
Self-citation
Metadata
- Authors
- McFarland, L.
- Affiliations
- University of Washington (US)
- Corresponding author
- McFarland, Lynne
- ORCID
- McFarland, Lynne
- Venue
- Antibiotics
- Publisher
- MDPI AG
- Published
- 2015-04-13
- Volume
- 4
- Issue
- 2
- Pages
- 160-178
- ISSN
- 2079-6382 (ISSN-L)
- PMC
- PMC4790329
- OpenAlex
- W2036627873
- Cited by
- 109
- References
- 60
- Citations by year
- 2026: 7 · 2025: 3 · 2024: 9 · 2023: 9 · 2022: 12 · 2021: 6 · 2020: 13 · 2019: 13 · 2018: 9 · 2017: 11 · 2016: 15 · 2015: 2
- FWCI
- 1.87
- Type
- journal article
- Language
- en
- Open access
- gold
- dx.doi.org
- Licence
- Locations
- Antibiotics (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Clostridium difficile and Clostridium perfringens research
- Life Sciences › Agricultural and Biological Sciences › Food Science › Probiotics and Fermented Foods
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Keywords
- probiotics, Clostridium difficile infection, primary prevention, secondary prevention, recurrence prevention, Saccharomyces boulardii, Lactobacillus casei, Lactobacillus acidophilus, Bifidobacterium bifidum, Lactobacillus rhamnosus, nosocomial infections, antibiotic-associated diarrhea
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.